Holzer & Holzer, LLC Reminds VTGN Investors of the March 16, 2026 Lead Plaintiff Deadline in the Vistagen Therapeutics, Inc. Securities Class Action

Group 1 - A shareholder class action lawsuit has been filed against Vistagen Therapeutics, Inc. alleging false and misleading statements regarding the risks of failure associated with its Phase 3 PALISADE-3 trial study of fasedienol [1] - The lawsuit targets investors who purchased Vistagen shares between April 1, 2024, and December 16, 2025, and experienced significant losses [2] - The deadline to request to be appointed as lead plaintiff in the case is March 16, 2026 [3]